A method of enhancing a mammalian immune response to a virus is disclosed. The method comprises administering a composition comprising an effective amount of epinecidin (Epi)-1the virus to a mammal, wherein the virus has envelope proteinis infectious to the mammal. In this technique, Epi-1Japanese encephalitis virus (JEV) were mixedinjected into mice. The mice were infected with JEV 14 days later,all mice survived. This technology has also been verified in the preparation of vaccines for foot-and-mouth disease virusnervous necrosis virus.

These stimuli-switchable nanoparticles coated with the cleavable outer polymer coatingmultifunctional peptides may afford a new platform for anticancer drugmiR. These nanoparticles possess characteristics of environmental response, active targeting,gene/chemo combinatorial therapeutics, thus providing spatiotemporal control of posttranｓｃｒｉｐｔional gene regulation, smart nuclear/mitochondrial localization,simultaneous inhibition of multiple progression pathways of tumor cells for enhancing antitumor efficacysafety of cancer therapy.

Chronic wound infection is a leading cause of mortality in injured patients worldwide. At present, available systemic antibiotic treatments have an insufficient tissue penetration ability and allow the development of antibiotic-resistant pathogens. The identification of therapeutic agents with wound healing and antimicrobial functions is necessary to heal the wound and cure infections. Our report shows that the antimicrobial peptide (AMP) Epinecidin-1 (Epi-1) efficiently heals MRSA-infected heat burn injuries and provides protection from infection in mouse and pig model. Our results demonstrate that the biomaterial Epi-1 heals wounds through increasing epithelial cell proliferation, vascularization, and the formation of collagen and controls MRSA infection-mediated sepsis in pigs.